Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aura Biosciences, Inc. (AURA)
USD6.97
-0.04 (-0.50%)
US NASDAQ Healthcare Biotechnology
Address
85 Bolton Street 2140
Boston, MA, US
Boston, MA, US
CEO
Elisabet de los Pinos
Website
aurabiosciences.com
IPO
2021-10-29
CIK 1501796 ISIN US05153U1079
Description
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.97
-0.04 (-0.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
614.6K
Beta
0.39
Float Shares
44.74M
Free Float %
69.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.40% | -2.35% | +5.96% | +26.83% | +13.18% | +37.06% | +27.47% | -34.47% | -49.53% | -49.53% | -49.53% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
6.97
Low
17.00
+144.1%
Consensus
17.00
+144.1%
Median
17.00
+144.1%
High
17.00
+144.1%
DCF (Unlevered)
0.67
-90.3%
DCF (Levered)
0.70
-90.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
17.00
+144.1%
|
| Last Quarter | 1 |
17.00
+144.1%
|
| Last Year | 1 |
17.00
+144.1%
|
| All Time | 8 |
22.63
+224.9%
|
Quality scores
Altman Z-Score
2.62
Grey zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-0.6% Q1'26: +9.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-1,122.4% Q1'26: -1,467.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+21.5% Q1'26: +34.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: -0.12× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 18.70M (-100.0%)
|
19.20M
13.89M – 24.50M
+2.7% YoY
|
7.72M
5.58M – 9.85M
-59.8% YoY
|
28.25M
20.44M – 36.05M
+266.0% YoY
|
108.38M
78.41M – 138.29M
+283.6% YoY
|
171.23M
123.88M – 218.47M
+58.0% YoY
|
| EBITDA |
-94.89M
|
-111.66M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-96.12M
|
-112.79M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-86.92M
est: -83.21M (-4.5%)
|
-106.19M
est: -118.22M (+10.2%)
|
-95.96M
-111.26M – -80.66M
+18.8% YoY
|
-97.28M
-112.73M – -81.82M
-1.4% YoY
|
-92.01M
-96.54M – -87.49M
+5.4% YoY
|
-66.37M
-90.18M – -42.51M
+27.9% YoY
|
-42.54M
-57.80M – -27.24M
+35.9% YoY
|
| SGA |
22.81M
|
22.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.75
est: -1.68 (-4.4%)
|
-1.76
est: -1.96 (+10.2%)
|
-1.60
-1.84 – -1.34
+18.6% YoY
|
-1.67
-1.87 – -1.36
-4.5% YoY
|
-1.53
-1.60 – -1.45
+8.5% YoY
|
-1.10
-1.49 – -0.70
+27.9% YoY
|
-0.71
-0.96 – -0.45
+35.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-29 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
127
Total invested
340.35M
Insider transactions (90d)
3
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 3.16M | 6.40% | 3.11M | — | 3.11M | — | HC | Delaware | 2024-11-08 | ↗ |
| 2 | Eventide Asset Management, LLC | 2.25M | 6.30% | 2.25M | — | 2.25M | — | IA | — | 2023-02-14 | ↗ |
| 3 | Finny Kuruvilla, M.D. Ph. D. | 2.25M | 6.30% | — | 2.25M | — | — | HC, IN | United States | 2023-02-14 | ↗ |
| 4 | Robin C. John | 2.25M | 6.30% | — | 2.25M | — | — | HC, IN | United States | 2023-02-14 | ↗ |
| 5 | Adage Capital Advisors, L.L.C. | 2.09M | 5.65% | — | 2.09M | — | — | OO | Delaware | 2022-12-15 | ↗ |
| 6 | Adage Capital Partners GP, L.L.C. | 2.09M | 5.65% | — | 2.09M | — | — | OO | Delaware | 2022-12-15 | ↗ |
| 7 | Adage Capital Partners, L.P. | 2.09M | 5.65% | — | 2.09M | — | — | PN | Delaware | 2022-12-15 | ↗ |
| 8 | Phillip Gross | 2.09M | 5.65% | — | 2.09M | — | — | IN | United States | 2022-12-15 | ↗ |
| 9 | Robert Atchinson | 2.09M | 5.65% | — | 2.09M | — | — | IN | United States | 2022-12-15 | ↗ |
| 10 | ALS III Carry and Co-Invest LP | 2.02M | 6.90% | — | 2.02M | — | 2.02M | PN | — | 2022-02-14 | ↗ |
| 11 | Advent Life Sciences Fund I LP | 2.02M | 6.90% | — | 2.02M | — | 2.02M | PN | — | 2022-02-14 | ↗ |
| 12 | Advent Life Sciences Fund III LP | 2.02M | 6.90% | — | 2.02M | — | 2.02M | PN | United Kingdom | 2022-02-14 | ↗ |
| 13 | Advent Life Sciences LLP | 2.02M | 6.90% | — | 2.02M | — | 2.02M | PN | — | 2022-02-14 | ↗ |
| 14 | Advent-Harrington Impact Fund LP | 2.02M | 6.90% | — | 2.02M | — | 2.02M | PN | — | 2022-02-14 | ↗ |
| 15 | Rajesh Parekh, Ph.D. | 2.02M | 6.90% | — | 2.02M | — | 2.02M | IN | — | 2022-02-14 | ↗ |
| 16 | (“Skole”) | 2.02M | 6.90% | 2.02M | — | 2.02M | — | IN | Denmark | 2022-01-26 | ↗ |
| 17 | Invest A/S (“Lundbeckfond”) | 2.02M | 6.90% | 2.02M | — | 2.02M | — | FI | Denmark | 2022-01-26 | ↗ |
| 18 | Chiesi Ventures, LP | 1.63M | 5.80% | — | 1.63M | — | — | PN | — | 2021-11-12 | ↗ |
| 19 | Giacomo Chiesi | 1.63M | 5.80% | — | 1.63M | — | — | IN | Italy | 2021-11-12 | ↗ |
| 20 | 2. | 10.00 | 0.00% | — | — | 13.00 | — | HC, PN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
127
+11 vs prev Q
New positions
23
Closed positions
13
Increased
63
Reduced
40
Put/Call ratio
0.00
Calls held
—
Puts held
338.3K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MATRIX CAPITAL MANAGEMENT COMPANY, LP | 6.92M +— (+0.0%) | 37.73M -5.1M (-11.8%) | 10.50% -1.434 pp | 65.48% +25.404 pp | USD13.98 -61.0% | 17 qtrs — |
| 2 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 5.10M +— (+0.0%) | 27.80M -3.7M (-11.8%) | 7.73% -1.056 pp | 0.75% -0.198 pp | USD6.26 -12.9% | 3 qtrs — |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.88M +— (+0.0%) | 26.60M -3.6M (-11.8%) | 7.40% -1.011 pp | 0.04% -0.008 pp | USD11.45 -52.4% | 17 qtrs — |
| 4 | LONG FOCUS CAPITAL MANAGEMENT, LLC | 4.62M +— (+0.0%) | 25.18M -3.4M (-11.8%) | 7.01% -0.957 pp | 0.66% -0.281 pp | USD7.23 -24.6% | 12 qtrs — |
| 5 | SUVRETTA CAPITAL MANAGEMENT, LLC | 4.37M +— (+0.0%) | 23.83M -3.2M (-11.8%) | 6.63% -0.906 pp | 0.49% -0.204 pp | USD6.01 -9.3% | 4 qtrs — |
| 6 | BLACKROCK, INC. | 3.56M +154.9K (+4.5%) | 19.40M -1.6M (-7.8%) | 5.40% -0.470 pp | 0.00% +0.000 pp | USD8.46 -35.6% | 6 qtrs — |
| 7 | MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 3.04M +— (+0.0%) | 16.57M -2.2M (-11.8%) | 4.61% -0.630 pp | 1.98% -0.540 pp | USD16.98 -67.9% | 17 qtrs — |
| 8 | VANGUARD GROUP INC | 2.94M +46.0K (+1.6%) | 16.00M -1.9M (-10.4%) | 4.45% -0.529 pp | 0.00% +0.000 pp | USD9.51 -42.7% | 17 qtrs — |
| 9 | FRANKLIN RESOURCES INC | 2.20M -492.0 (0.0%) | 11.98M -1.6M (-11.8%) | 3.33% -0.456 pp | 0.00% 0.000 pp | USD7.68 -29.0% | 9 qtrs — |
| 10 | NANTAHALA CAPITAL MANAGEMENT, LLC | 2.12M +— (+0.0%) | 11.54M -1.5M (-11.8%) | 3.21% -0.439 pp | 0.38% -0.073 pp | USD9.72 -43.9% | 17 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1.26M -2.5K (-0.2%) | 6.85M -930.2K (-12.0%) | 1.90% -0.264 pp | 0.00% 0.000 pp | USD9.58 -43.1% | 17 qtrs — |
| 12 | LEVIN CAPITAL STRATEGIES, L.P. | 1.04M -591.7K (-36.4%) | 5.64M -4.4M (-43.9%) | 1.57% -1.234 pp | 0.49% -0.422 pp | USD7.81 -30.2% | 12 qtrs — |
| 13 | STATE STREET CORP | 926.5K +47.7K (+5.4%) | 5.05M -381.8K (-7.0%) | 1.41% -0.110 pp | 0.00% +0.000 pp | USD10.84 -49.7% | 17 qtrs — |
| 14 | MILLENNIUM MANAGEMENT LLC | 617.3K +432.1K (+233.3%) | 3.36M +2.2M (+193.9%) | 0.94% +0.617 pp | 0.00% +0.001 pp | USD5.69 -4.2% | 3 qtrs — |
| 15 | ACORN CAPITAL ADVISORS, LLC | 595.7K +— (+0.0%) | 3.25M -434.9K (-11.8%) | 0.90% -0.123 pp | 1.10% -0.769 pp | USD5.86 -7.0% | 4 qtrs — |
| 16 | B GROUP, INC. | 572.6K +— (+0.0%) | 3.12M -418.0K (-11.8%) | 0.87% -0.119 pp | 2.30% -0.299 pp | USD7.88 -30.8% | 5 qtrs — |
| 17 | REGENCY CAPITAL MANAGEMENT INC.\DE | 538.6K -74.1K (-12.1%) | 2.94M -851.1K (-22.5%) | 0.82% -0.239 pp | 1.22% -0.580 pp | USD9.91 -45.0% | 15 qtrs — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 517.9K +20.6K (+4.2%) | 2.82M -250.3K (-8.1%) | 0.79% -0.072 pp | 0.00% 0.000 pp | USD8.04 -32.2% | 11 qtrs — |
| 19 | PRICE T ROWE ASSOCIATES INC /MD/ | 442.8K -38.4K (-8.0%) | 2.42M -560.0K (-18.8%) | 0.67% -0.158 pp | 0.00% 0.000 pp | USD10.33 -47.2% | 13 qtrs — |
| 20 | NORTHERN TRUST CORP | 412.8K -20.8K (-4.8%) | 2.25M -430.1K (-16.0%) | 0.63% -0.121 pp | 0.00% 0.000 pp | USD10.56 -48.4% | 17 qtrs — |
| 21 | DECHENG CAPITAL LLC | 360.5K -155.1K (-30.1%) | 1.96M -1.2M (-38.3%) | 0.55% -0.342 pp | 0.26% -0.292 pp | USD8.86 -38.5% | 9 qtrs — |
| 22 | MORGAN STANLEY | 218.4K +39.9K (+22.4%) | 1.19M +87.2K (+7.9%) | 0.33% +0.024 pp | 0.00% +0.000 pp | USD7.50 -27.3% | 17 qtrs — |
| 23 | UBS GROUP AG | 171.6K -725.2K (-80.9%) | 935.4K -4.6M (-83.1%) | 0.26% -1.286 pp | 0.00% -0.001 pp | USD7.75 -29.7% | 17 qtrs — |
| 24 | BANK OF AMERICA CORP /DE/ | 165.2K +129.0K (+356.5%) | 900.3K +676.6K (+302.6%) | 0.25% +0.188 pp | 0.00% +0.000 pp | USD6.52 -16.4% | 17 qtrs — |
| 25 | RENAISSANCE TECHNOLOGIES LLC | 145.2K +47.6K (+48.8%) | 791.3K +188.1K (+31.2%) | 0.22% +0.052 pp | 0.00% +0.000 pp | USD6.82 -20.1% | 13 qtrs — |
| 26 | WELLINGTON MANAGEMENT GROUP LLP | 141.0K +13.6K (+10.7%) | 768.2K -18.6K (-2.4%) | 0.21% -0.006 pp | 0.00% +0.000 pp | USD7.77 -29.9% | 6 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 139.9K -55.0K (-28.2%) | 762.6K -442.2K (-36.7%) | 0.21% -0.124 pp | 0.00% 0.000 pp | USD8.76 -37.8% | 13 qtrs — |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 135.1K +115.0 (+0.1%) | 736.1K -97.9K (-11.7%) | 0.20% -0.028 pp | 0.00% +0.000 pp | USD10.53 -48.2% | 17 qtrs — |
| 29 | BNP PARIBAS ARBITRAGE, SNC | 114.6K +82.4K (+255.8%) | 624.6K +425.6K (+213.8%) | 0.17% +0.118 pp | 0.00% +0.000 pp | USD5.72 -4.7% | 5 qtrs — |
| 30 | PLATINUM INVESTMENT MANAGEMENT LTD | 111.9K -23.5K (-17.4%) | 609.7K -227.1K (-27.1%) | 0.17% -0.064 pp | 0.14% +0.087 pp | USD8.86 -38.5% | 9 qtrs — |
| 31 | BANK OF NEW YORK MELLON CORP | 107.9K +12.2K (+12.7%) | 588.2K -3.5K (-0.6%) | 0.16% -0.001 pp | 0.00% +0.000 pp | USD10.85 -49.8% | 16 qtrs — |
| 32 | RESOLUTE CAPITAL ASSET PARTNERS LLC | 91.0K +— (+0.0%) | 496.0K -66.4K (-11.8%) | 0.14% -0.019 pp | 0.24% -0.055 pp | USD6.26 -12.9% | 3 qtrs — |
| 33 | PERMANENT CAPITAL MANAGEMENT, LP | 75.9K -71.9K (-48.7%) | 413.5K -499.8K (-54.7%) | 0.12% -0.140 pp | 0.08% -0.090 pp | USD6.18 -11.8% | 2 qtrs — |
| 34 | NUVEEN, LLC | 72.3K +— (+0.0%) | 394.2K -52.8K (-11.8%) | 0.11% -0.015 pp | 0.00% +0.000 pp | USD5.86 -7.0% | 4 qtrs — |
| 35 | BARCLAYS PLC | 69.3K +8.3K (+13.6%) | 377.7K -165.9K (-30.5%) | 0.11% 0.000 pp | 0.00% +0.000 pp | USD8.05 -32.3% | 16 qtrs — |
| 36 | CITADEL ADVISORS LLC | 68.5K +68.5K (+100.0%) | 373.6K +373.6K (+100.0%) | 0.10% +0.104 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 17 qtrs — |
| 37 | RHUMBLINE ADVISERS | 65.0K -4.0K (-5.8%) | 354.4K -72.2K (-16.9%) | 0.10% -0.020 pp | 0.00% 0.000 pp | USD10.30 -47.1% | 15 qtrs — |
| 38 | XTX TOPCO LTD | 60.8K +36.0K (+145.2%) | 331.4K +178.1K (+116.2%) | 0.09% +0.050 pp | 0.01% +0.001 pp | USD5.75 -5.2% | 2 qtrs — |
| 39 | TBH GLOBAL ASSET MANAGEMENT, LLC | 60.3K +— (+0.0%) | 328.8K -44.0K (-11.8%) | 0.09% -0.013 pp | 0.05% -0.018 pp | USD9.09 -40.0% | 12 qtrs — |
| 40 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 59.2K -419.0 (-0.7%) | 324.6K -44.1K (-12.0%) | 0.09% -0.013 pp | 0.00% +0.000 pp | USD10.02 -45.6% | 13 qtrs — |
| 41 | POINT72 ASSET MANAGEMENT, L.P. | 54.7K +54.7K (+100.0%) | 298.1K +298.1K (+100.0%) | 0.08% +0.083 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 42 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 51.4K +8.0K (+18.4%) | 280.2K +11.9K (+4.4%) | 0.08% +0.003 pp | 0.00% -0.001 pp | USD6.13 -11.1% | 3 qtrs — |
| 43 | PRELUDE CAPITAL MANAGEMENT, LLC | 50.0K +— (+0.0%) | 272.5K -36.5K (-11.8%) | 0.08% -0.010 pp | 0.02% -0.004 pp | USD6.18 -11.8% | 2 qtrs — |
| 44 | WELLS FARGO & COMPANY/MN | 49.1K +17.3K (+54.7%) | 267.3K +71.4K (+36.4%) | 0.07% +0.020 pp | 0.00% +0.000 pp | USD7.04 -22.6% | 17 qtrs — |
| 45 | JANE STREET GROUP, LLC | 47.4K +14.3K (+43.3%) | 258.5K +53.9K (+26.4%) | 0.07% +0.015 pp | 0.00% +0.000 pp | USD5.96 -8.6% | 2 qtrs — |
| 46 | WALLEYE CAPITAL LLC | 46.4K -20.9K (-31.1%) | 252.7K -163.2K (-39.2%) | 0.07% -0.046 pp | 0.00% -0.001 pp | USD6.18 -11.8% | 2 qtrs — |
| 47 | TREXQUANT INVESTMENT LP | 43.0K +43.0K (+100.0%) | 234.3K +234.3K (+100.0%) | 0.07% +0.065 pp | 0.00% +0.002 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 48 | AMERIPRISE FINANCIAL INC | 42.8K -77.9K (-64.5%) | 233.5K -512.7K (-68.7%) | 0.07% -0.143 pp | 0.00% 0.000 pp | USD7.65 -28.8% | 6 qtrs — |
| 49 | ALLIANCEBERNSTEIN L.P. | 41.7K +— (+0.0%) | 227.0K -30.4K (-11.8%) | 0.06% -0.009 pp | 0.00% +0.000 pp | USD8.26 -34.0% | 11 qtrs — |
| 50 | AMERICAN CENTURY COMPANIES INC | 40.7K +2.1K (+5.3%) | 222.1K -17.1K (-7.1%) | 0.06% -0.005 pp | 0.00% +0.000 pp | USD7.91 -31.1% | 7 qtrs — |
| 51 | TD ASSET MANAGEMENT INC | 40.5K -28.5K (-41.3%) | 220.7K -205.9K (-48.3%) | 0.06% -0.058 pp | 0.00% 0.000 pp | USD9.54 -42.9% | 13 qtrs — |
| 52 | QUANTINNO CAPITAL MANAGEMENT LP | 36.4K -8.3K (-18.5%) | 198.3K -77.6K (-28.1%) | 0.06% -0.022 pp | 0.00% 0.000 pp | USD6.22 -12.4% | 3 qtrs — |
| 53 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 36.1K -20.7K (-36.5%) | 196.7K -154.3K (-44.0%) | 0.05% -0.043 pp | 0.00% -0.003 pp | USD6.26 -12.9% | 3 qtrs — |
| 54 | CITIGROUP INC | 34.9K +29.5K (+542.1%) | 190.2K +156.6K (+466.3%) | 0.05% +0.044 pp | 0.00% +0.000 pp | USD5.98 -8.9% | 17 qtrs — |
| 55 | HARBOR CAPITAL ADVISORS, INC. | 33.0K +6.5K (+24.5%) | 180.0K +16.0K (+9.8%) | 0.05% +0.004 pp | 0.01% +0.001 pp | USD5.85 -6.8% | 4 qtrs — |
| 56 | DEUTSCHE BANK AG\ | 30.8K -14.6K (-32.2%) | 168.0K -112.9K (-40.2%) | 0.05% -0.032 pp | 0.00% +0.000 pp | USD6.18 -11.8% | 17 qtrs — |
| 57 | COMMONWEALTH EQUITY SERVICES, LLC | 30.3K -568.0 (-1.8%) | 165.1K -26.0K (-13.6%) | 0.05% -0.007 pp | 0.00% +0.000 pp | USD7.58 -28.1% | 7 qtrs — |
| 58 | LETKO, BROSSEAU & ASSOCIATES INC | 28.3K +— (+0.0%) | 154.2K -20.7K (-11.8%) | 0.04% -0.006 pp | 0.00% -0.001 pp | USD7.36 -26.0% | 8 qtrs — |
| 59 | INVESCO LTD. | 27.3K -3.1K (-10.1%) | 148.7K -38.8K (-20.7%) | 0.04% -0.011 pp | 0.00% +0.000 pp | USD6.21 -12.2% | 3 qtrs — |
| 60 | ENTRYPOINT CAPITAL, LLC | 26.3K +26.3K (+100.0%) | 143.3K +143.3K (+100.0%) | 0.04% +0.040 pp | 0.06% +0.056 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 61 | METLIFE INVESTMENT MANAGEMENT, LLC | 25.0K +5.7K (+29.3%) | 136.4K +16.8K (+14.0%) | 0.04% +0.005 pp | 0.00% +0.000 pp | USD9.59 -43.2% | 15 qtrs — |
| 62 | — | 22.0K +22.0K (+100.0%) | 126.7K +126.7K (+100.0%) | 0.03% +0.033 pp | 0.03% +0.032 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 63 | JPMORGAN CHASE & CO | 23.1K -1.4K (-5.9%) | 126.0K -25.8K (-17.0%) | 0.04% -0.007 pp | 0.00% +0.000 pp | USD8.86 -38.5% | 17 qtrs — |
| 64 | INTECH INVESTMENT MANAGEMENT LLC | 21.0K +5.5K (+35.9%) | 114.4K +18.9K (+19.8%) | 0.03% +0.005 pp | 0.00% +0.000 pp | USD7.16 -23.9% | 5 qtrs — |
| 65 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 20.4K -44.0 (-0.2%) | 111.0K -15.1K (-12.0%) | 0.03% -0.004 pp | 0.00% +0.000 pp | USD7.76 -29.8% | 7 qtrs — |
| 66 | 49 WEALTH MANAGEMENT, LLC | 19.0K +8.4K (+78.9%) | 103.5K +37.9K (+57.8%) | 0.03% +0.011 pp | 0.01% +0.002 pp | USD5.86 -7.0% | 2 qtrs — |
| 67 | CANADA PENSION PLAN INVESTMENT BOARD | 18.7K +18.7K (+100.0%) | 101.9K +101.9K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 68 | ETHIC INC. | 17.5K +2.6K (+17.4%) | 95.6K +3.3K (+3.5%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD6.07 -10.2% | 2 qtrs — |
| 69 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 16.3K +— (+0.0%) | 88.7K -11.9K (-11.8%) | 0.02% -0.003 pp | 0.00% 0.000 pp | USD6.26 -12.9% | 3 qtrs — |
| 70 | MIRABELLA FINANCIAL SERVICES LLP | 14.1K +14.1K (+100.0%) | 76.9K +76.9K (+100.0%) | 0.02% +0.021 pp | 0.01% +0.007 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 71 | AQR CAPITAL MANAGEMENT LLC | 13.9K -3.3K (-19.2%) | 75.5K -30.5K (-28.7%) | 0.02% -0.009 pp | 0.00% +0.000 pp | USD6.26 -12.9% | 3 qtrs — |
| 72 | BROWN ADVISORY INC | 13.4K +13.4K (+100.0%) | 73.0K +73.0K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 73 | NEW YORK STATE COMMON RETIREMENT FUND | 13.1K +— (+0.0%) | 71.4K -9.6K (-11.8%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD12.65 -56.9% | 17 qtrs — |
| 74 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 11.4K +— (+0.0%) | 62.1K -8.3K (-11.8%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD8.22 -33.7% | 5 qtrs — |
| 75 | CREATIVE PLANNING | 11.3K +11.3K (+100.0%) | 61.6K +61.6K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 76 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 11.7K -93.0 (-0.8%) | 60.5K -7.6K (-11.1%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD7.70 -29.2% | 8 qtrs — |
| 77 | PROSHARE ADVISORS LLC | 10.8K +10.8K (+100.0%) | 59.0K +59.0K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 5 qtrs — |
| 78 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 10.3K -541.0 (-5.0%) | 56.4K -10.9K (-16.2%) | 0.02% -0.003 pp | 0.00% -0.001 pp | USD7.84 -30.5% | 5 qtrs — |
| 79 | FMR LLC | 8.1K +4.7K (+134.7%) | 44.4K +22.9K (+107.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD7.54 -27.7% | 17 qtrs — |
| 80 | AMERITAS INVESTMENT PARTNERS, INC. | 4.5K +— (+0.0%) | 24.8K -3.3K (-11.8%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD10.67 -48.9% | 17 qtrs — |
| 81 | LEGAL & GENERAL GROUP PLC | 4.3K +— (+0.0%) | 23.7K -3.2K (-11.8%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD11.27 -51.6% | 17 qtrs — |
| 82 | RUSSELL INVESTMENTS GROUP, LTD. | 3.7K +— (+0.0%) | 20.4K -2.7K (-11.8%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD6.21 -12.2% | 7 qtrs — |
| 83 | ROYAL BANK OF CANADA | 3.1K -39.5K (-92.8%) | 17.0K -246.0K (-93.5%) | 0.00% -0.069 pp | 0.00% +0.000 pp | USD6.48 -15.9% | 17 qtrs — |
| 84 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 3.1K +684.0 (+28.5%) | 16.8K +2.0K (+13.3%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD7.13 -23.6% | 5 qtrs — |
| 85 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2.7K +369.0 (+15.8%) | 14.7K +307.0 (+2.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.79 -57.4% | 17 qtrs — |
| 86 | SIMPLEX TRADING, LLC | 2.6K +2.6K (+100.0%) | 14.4K +14.4K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 87 | PARALLEL ADVISORS, LLC | 2.5K +2.4K (+3,012.7%) | 13.4K +12.9K (+2,646.3%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD5.48 -0.5% | 3 qtrs — |
| 88 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.0K -261.0 (-11.8%) | 10.7K -3.0K (-22.2%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD7.50 -27.3% | 17 qtrs — |
| 89 | STERLING CAPITAL MANAGEMENT LLC | 1.8K -279.0 (-13.4%) | 9.8K -3.0K (-23.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD6.90 -21.0% | 6 qtrs — |
| 90 | SMARTLEAF ASSET MANAGEMENT LLC | 1.7K +478.0 (+37.8%) | 9.6K +1.8K (+22.7%) | 0.00% +0.001 pp | 0.00% 0.000 pp | USD6.17 -11.7% | 6 qtrs — |
| 91 | COMERICA BANK | 1.6K +578.0 (+55.2%) | 8.9K +2.4K (+36.9%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.97 -8.7% | 5 qtrs — |
| 92 | UBS ASSET MANAGEMENT AMERICAS INC | 1.6K +1.6K (+100.0%) | 8.7K +8.7K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 93 | AMALGAMATED BANK | 1.4K -221.0 (-13.8%) | 8.0K -2.0K (-20.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD13.59 -59.9% | 16 qtrs — |
| 94 | GF FUND MANAGEMENT CO. LTD. | 1.2K -89.0 (-6.7%) | 6.8K -1.5K (-17.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD7.72 -29.4% | 5 qtrs — |
| 95 | ADVISOR GROUP HOLDINGS, INC. | 926.00 +673.0 (+266.0%) | 5.0K +3.5K (+222.6%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.67 -3.9% | 7 qtrs — |
| 96 | VERSANT CAPITAL MANAGEMENT, INC | 793.00 +793.0 (+100.0%) | 4.3K +4.3K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.001 pp | USD5.45 +0.0% | 4 qtrs — |
| 97 | CWM, LLC | 811.00 -494.0 (-37.9%) | 4.0K -4.0K (-50.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD6.32 -13.8% | 7 qtrs — |
| 98 | SBI SECURITIES CO., LTD. | 634.00 -2.0 (-0.3%) | 3.5K -475.0 (-12.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD7.29 -25.2% | 5 qtrs — |
| 99 | OPTIVER HOLDING B.V. | 584.00 +584.0 (+100.0%) | 3.2K +3.2K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 1 qtrs NEW |
| 100 | IFP ADVISORS, INC | 363.00 +362.0 (+36,200.0%) | 2.0K +2.0K (+32,866.7%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.45 +0.0% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 70 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.66% | 378.1K | 0.65% |
| 2 | iShares Micro-Cap ETF IWC | 0.07% | 1.03M | 0.60% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.05% | 449.1K | 0.40% |
| 4 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.05% | 224.9K | 0.40% |
| 5 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.05% | 36.3K | 0.19% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.05% | 35.6K | 0.35% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.05% | 532.3K | 0.35% |
| 8 | Schwab International Small-Cap Equity ETF SCHC | 0.03% | 1.85M | 0.06% |
| 9 | iShares Biotechnology ETF IBB | 0.03% | 3.18M | 0.44% |
| 10 | Fidelity Enhanced Small Cap ETF FESM | 0.03% | 1.79M | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.50
Neutral
Ratio by volume
0.48
Bearish
Buys
3
Sells
2
Shares acquired
3.32M
Shares disposed
6.93M
Cash buys
—
Cash sales
2.00
Net activity
-3,611,543
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | Holles Natalie C. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,169,103 | 7.39 | 16.03M | 2,169,103 | D | ↗ |
| 2026-05-07 | Matrix Capital Management Company, LP | 10% Owner | S-Sale | D | Common Stock, par value $0.00001 per share (Common Stock) | 6,922,870 | 5.64 | 39.04M | 0 | I | ↗ |
| 2026-04-30 | Holles Natalie C. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-04-16 | Kilroy Conor | Officer | S-Sale | D | Common Stock | 11,738 | 7.02 | 82.4K | 217,835 | D | ↗ |
| 2026-03-02 | de los Pinos Elisabet | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 249,000 | 6.14 | 1.53M | 249,000 | D | ↗ |
| 2026-03-02 | Plavsic Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 112,661 | 6.14 | 691.7K | 112,661 | D | ↗ |
| 2026-03-02 | Kilroy Conor | Officer | A-Award | A | Stock Option (Right to Buy) | 112,661 | 6.14 | 691.7K | 112,661 | D | ↗ |
| 2026-03-02 | Hopkins Janet Jill | Officer | A-Award | A | Stock Option (Right to Buy) | 160,944 | 6.14 | 988.2K | 160,944 | D | ↗ |
| 2026-03-02 | Gibney Anthony S | Officer | A-Award | A | Stock Option (Right to Buy) | 128,755 | 6.14 | 790.6K | 128,755 | D | ↗ |
| 2026-03-02 | Elazzouzi Amy | Officer | A-Award | A | Stock Option (Right to Buy) | 80,472 | 6.14 | 494.1K | 80,472 | D | ↗ |
| 2026-02-17 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 47,648 | 5.06 | 241.1K | 409,815 | D | ↗ |
| 2026-02-17 | Plavsic Mark | Officer | S-Sale | D | Common Stock | 15,890 | 5.05 | 80.2K | 181,397 | D | ↗ |
| 2026-02-17 | Kilroy Conor | Officer | S-Sale | D | Common Stock | 12,079 | 5.05 | 61.0K | 167,234 | D | ↗ |
| 2026-02-17 | Hopkins Janet Jill | Officer | S-Sale | D | Common Stock | 20,401 | 5.06 | 103.2K | 232,284 | D | ↗ |
| 2026-02-17 | Elazzouzi Amy | Officer | S-Sale | D | Common Stock | 8,549 | 5.06 | 43.3K | 75,532 | D | ↗ |
| 2026-01-20 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 16,928 | 4.86 | 82.3K | 457,463 | D | ↗ |
| 2026-01-20 | Elazzouzi Amy | Officer | S-Sale | D | Common Stock | 1,581 | 4.86 | 7.7K | 84,081 | D | ↗ |
| 2025-11-17 | Hopkins Janet Jill | Officer | S-Sale | D | Common Stock | 17,109 | 5.42 | 92.7K | 252,685 | D | ↗ |
| 2025-10-29 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 9,049 | 6.35 | 57.5K | 474,391 | D | ↗ |
| 2025-10-29 | Elazzouzi Amy | Officer | S-Sale | D | Common Stock | 896 | 6.35 | 5.7K | 85,662 | D | ↗ |
| 2025-10-16 | Plavsic Mark | Officer | S-Sale | D | Common Stock | 12,169 | 6.35 | 77.3K | 197,287 | D | ↗ |
| 2025-08-18 | Elazzouzi Amy | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,094 | 3.16 | 3.5K | 0 | D | ↗ |
| 2025-06-17 | Srivastava Sapna | Director | A-Award | A | Stock Option (Right to Buy) | 17,000 | 6.18 | 105.1K | 17,000 | D | ↗ |
| 2025-06-17 | Mattessich Antony C. | Director | A-Award | A | Stock Option (Right to Buy) | 17,000 | 6.18 | 105.1K | 17,000 | D | ↗ |
| 2025-06-17 | Johnson David Michael | Director | A-Award | A | Stock Option (Right to Buy) | 17,000 | 6.18 | 105.1K | 17,000 | D | ↗ |
| 2025-06-02 | de los Pinos Elisabet | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,948 | 5.07 | 55.5K | 0 | D | ↗ |
| 2025-06-02 | Gibney Anthony S | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 6.16 | 1.54M | 250,000 | D | ↗ |
| 2025-05-16 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 20,000 | 4.90 | 98.0K | 166,167 | D | ↗ |
| 2025-05-16 | Gibney Anthony S | Officer | S-Sale | D | Common Stock | 1,519 | 5.15 | 7.8K | 56,933 | D | ↗ |
| 2025-05-13 | Gibney Anthony S | Officer | — | — | Common Stock | 0 | 0.00 | — | 8,452 | D | ↗ |
| 2025-04-16 | Kilroy Conor | Officer | S-Sale | D | Common Stock | 7,162 | 5.49 | 39.3K | 179,313 | D | ↗ |
| 2025-04-16 | Elazzouzi Amy | Officer | S-Sale | D | Common Stock | 897 | 5.49 | 4.9K | 81,381 | D | ↗ |
| 2025-03-31 | Bitetti Teresa Marie | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-18 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 20,221 | 7.75 | 156.8K | 482,440 | D | ↗ |
| 2025-02-18 | Plavsic Mark | Officer | S-Sale | D | Common Stock | 2,151 | 7.75 | 16.7K | 209,456 | D | ↗ |
| 2025-02-18 | Hopkins Janet Jill | Officer | S-Sale | D | Common Stock | 2,534 | 7.75 | 19.6K | 269,794 | D | ↗ |
| 2025-02-18 | Elazzouzi Amy | Officer | S-Sale | D | Common Stock | 1,404 | 7.75 | 10.9K | 82,278 | D | ↗ |
| 2025-02-03 | de los Pinos Elisabet | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 255,680 | 7.68 | 1.96M | 255,680 | D | ↗ |
| 2025-02-03 | Plavsic Mark | Officer | A-Award | A | Common Stock | 90,475 | 0.00 | — | 211,607 | D | ↗ |
| 2025-02-03 | Kilroy Conor | Officer | A-Award | A | Stock Option (Right to Buy) | 59,525 | 7.68 | 457.2K | 59,525 | D | ↗ |
| 2025-02-03 | Hopkins Janet Jill | Officer | A-Award | A | Stock Option (Right to Buy) | 79,365 | 7.68 | 609.5K | 79,365 | D | ↗ |
| 2025-02-03 | Elazzouzi Amy | Officer | A-Award | A | Stock Option (Right to Buy) | 29,760 | 7.68 | 228.6K | 29,760 | D | ↗ |
| 2025-01-21 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 15,955 | 7.67 | 122.4K | 304,692 | D | ↗ |
| 2025-01-21 | Elazzouzi Amy | Officer | S-Sale | D | Common Stock | 1,001 | 7.67 | 7.7K | 38,442 | D | ↗ |
| 2024-11-18 | Hopkins Janet Jill | Officer | S-Sale | D | Common Stock | 11,822 | 9.36 | 110.7K | 151,693 | D | ↗ |
| 2024-10-29 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 9,200 | 10.74 | 98.8K | 320,647 | D | ↗ |
| 2024-10-29 | Elazzouzi Amy | Officer | S-Sale | D | Common Stock | 553 | 10.74 | 5.9K | 39,443 | D | ↗ |
| 2024-10-25 | Elazzouzi Amy | Officer | — | — | Stock Option (Right to Buy) | 1,094 | 3.16 | 3.5K | 0 | D | ↗ |
| 2024-10-18 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 24,992 | 12.04 | 300.8K | 329,847 | D | ↗ |
| 2024-10-18 | Feder Julie B | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 5.48 | 27.4K | 120,547 | D | ↗ |
| 2024-10-16 | Plavsic Mark | Officer | S-Sale | D | Common Stock | 7,383 | 9.85 | 72.7K | 121,132 | D | ↗ |
| 2024-09-27 | de los Pinos Elisabet | Director / Officer | M-Exempt | A | Common Stock | 5,474 | 5.76 | 31.5K | 329,847 | D | ↗ |
| 2024-06-20 | Srivastava Sapna | Director | A-Award | A | Stock Option (Right to Buy) | 14,500 | 6.93 | 100.5K | 14,500 | — | ↗ |
| 2024-06-20 | Mattessich Antony C. | Director | A-Award | A | Common Stock | 10,500 | 0.00 | — | 10,500 | — | ↗ |
| 2024-06-20 | Johnson David Michael | Director | A-Award | A | Common Stock | 10,500 | 0.00 | — | 146,167 | — | ↗ |
| 2024-04-02 | Kilroy Conor | Officer | A-Award | A | Stock Option (Right to Buy) | 144,000 | 7.40 | 1.07M | 144,000 | — | ↗ |
| 2024-04-01 | Kilroy Conor | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-15 | Plavsic Mark | Officer | — | D | Common Stock | 0 | 0.00 | — | 128,515 | — | ↗ |
| 2024-02-01 | de los Pinos Elisabet | Director / Officer | A-Award | A | Common Stock | 162,935 | 0.00 | — | 324,373 | — | ↗ |
| 2024-02-01 | Hopkins Janet Jill | Officer | A-Award | A | Common Stock | 28,515 | 0.00 | — | 163,515 | — | ↗ |
| 2024-02-01 | Feder Julie B | Officer | A-Award | A | Common Stock | 71,285 | 0.00 | — | 134,276 | — | ↗ |
| 2024-01-23 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 15,853 | 7.64 | 121.1K | 161,438 | — | ↗ |
| 2024-01-23 | Feder Julie B | Officer | S-Sale | D | Common Stock | 6,609 | 7.64 | 50.5K | 62,991 | — | ↗ |
| 2023-11-09 | Matrix Capital Management Company, LP | 10% Owner | P-Purchase | A | Common Stock, par value $0.00001 per share (Common Stock) | 1,560,000 | 9.00 | 14.04M | 6,922,870 | — | ↗ |
| 2023-11-08 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 10,000 | 7.30 | 73.0K | 75,000 | — | ↗ |
| 2023-11-07 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 76,000 | 7.17 | 544.9K | 126,066 | — | ↗ |
| 2023-11-06 | de los Pinos Elisabet | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,800 | 2.74 | 10.4K | 361,163 | — | ↗ |
| 2023-11-06 | Feder Julie B | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,900 | 2.74 | 10.7K | 85,757 | — | ↗ |
| 2023-11-01 | Hopkins Janet Jill | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 8.97 | 1.79M | 200,000 | — | ↗ |
| 2023-10-30 | de los Pinos Elisabet | Director / Officer | S-Sale | D | Common Stock | 9,586 | 6.83 | 65.5K | 180,940 | — | ↗ |
| 2023-10-30 | Feder Julie B | Officer | S-Sale | D | Common Stock | 3,385 | 6.82 | 23.1K | 69,600 | — | ↗ |
| 2023-10-16 | Hopkins Janet Jill | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-04 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 6,566 | 8.61 | 56.5K | 50,066 | — | ↗ |
| 2023-10-03 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 13,500 | 8.27 | 111.7K | 43,500 | — | ↗ |
| 2023-06-07 | Srivastava Sapna | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 12.83 | 205.3K | 16,000 | — | ↗ |
| 2023-06-07 | PAREKH RAJESH B | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 12.83 | 205.3K | 16,000 | — | ↗ |
| 2023-06-07 | Mattessich Antony C. | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 12.83 | 205.3K | 16,000 | — | ↗ |
| 2023-06-07 | Johnson David Michael | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 12.83 | 205.3K | 16,000 | — | ↗ |
| 2023-01-19 | de los Pinos Elisabet | Officer | A-Award | A | Stock Option (Right to Buy) | 187,500 | 0.00 | — | 187,500 | — | ↗ |
| 2023-01-19 | Rich Cadmus | Officer | A-Award | A | Stock Option (Right to Buy) | 52,500 | 0.00 | — | 52,500 | — | ↗ |
| 2023-01-19 | Feder Julie B | Officer | A-Award | A | Common Stock | 48,750 | 0.00 | — | 72,985 | — | ↗ |
| 2023-01-19 | De Rosch Mark | Officer | A-Award | A | Common Stock | 42,250 | 0.00 | — | 58,635 | — | ↗ |
| 2023-01-06 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 904 | 10.51 | 9.5K | 18,000 | — | ↗ |
| 2023-01-05 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 300 | 10.00 | 3.0K | 17,300 | — | ↗ |
| 2022-12-28 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 2,000 | 9.75 | 19.5K | 17,000 | — | ↗ |
| 2022-12-05 | Matrix Capital Management Company, LP | Director | P-Purchase | A | Common Stock, par value $0.00001 per share ("Common Stock") | 1,250,000 | 12.00 | 15.00M | 5,362,870 | — | ↗ |
| 2022-12-01 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 5,000 | 12.37 | 61.9K | 15,000 | — | ↗ |
| 2022-10-31 | de los Pinos Elisabet | Officer | S-Sale | D | Common Stock | 5,706 | 12.46 | 71.1K | 68,651 | — | ↗ |
| 2022-10-31 | Rich Cadmus | Officer | S-Sale | D | Common Stock | 1,672 | 12.45 | 20.8K | 24,578 | — | ↗ |
| 2022-10-31 | Feder Julie B | Officer | S-Sale | D | Common Stock | 2,015 | 12.45 | 25.1K | 24,235 | — | ↗ |
| 2022-10-31 | De Rosch Mark | Officer | S-Sale | D | Common Stock | 1,115 | 12.46 | 13.9K | 16,385 | — | ↗ |
| 2022-06-15 | Srivastava Sapna | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-15 | PAREKH RAJESH B | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-15 | Mattessich Antony C. | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-15 | Johnson David Michael | Director | A-Award | A | Stock Option (Right to Buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-06-13 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 20,000 | 13.99 | 279.8K | 30,000 | — | ↗ |
| 2022-06-10 | Johnson David Michael | Director | P-Purchase | A | Common Stock | 10,000 | 15.04 | 150.4K | 10,000 | — | ↗ |
| 2021-11-02 | de los Pinos Elisabet | Officer | C-Conversion | D | Series A-2 Preferred Stock | 1,510 | — | — | 0 | — | ↗ |
| 2021-11-02 | Medicxi Ventures Management (Jersey) Ltd | Director | C-Conversion | D | Series E Convertible Preferred Stock | 5,975 | 0.00 | — | 0 | — | ↗ |
| 2021-11-02 | Matrix Capital Management Company, LP | Director | C-Conversion | A | Common Stock, par value $0.00001 per share ("Common Stock") | 2,327,870 | — | — | 2,327,870 | — | ↗ |
| 2021-11-02 | Johnson David Michael | Director | C-Conversion | D | Series E Convertible Preferred Stock | 139,672 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | de los Pinos Elisabet | Officer | — | I | Common Stock | 0 | 0.00 | — | 126,860 | — | ↗ |
| 2021-10-28 | Takhar Karan S. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Srivastava Sapna | Director | — | D | Stock Option (Right to Buy) | 53,649 | 5.48 | 294.0K | 0 | — | ↗ |
| 2021-10-28 | Rich Cadmus | Officer | — | D | Stock Option (Right to Buy) | 125,547 | 5.48 | 688.0K | 0 | — | ↗ |
| 2021-10-28 | Primiano Christopher Brett | Officer | — | D | Stock Option (Right to Buy) | 124,087 | 9.59 | 1.19M | 0 | — | ↗ |
| 2021-10-28 | PAREKH RAJESH B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Medicxi Ventures Management (Jersey) Ltd | Director | — | I | Series E Convertible Preferred Stock | 5,975 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Mattessich Antony C. | Director | — | D | Stock Option (Right to Buy) | 53,649 | 9.59 | 514.5K | 0 | — | ↗ |
| 2021-10-28 | Matrix Capital Management Company, LP | Director | — | I | Series E Convertible Preferred Stock | 2,327,870 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Mariggi Giovanni | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Johnson David Michael | Director | — | D | Stock Option (Right to Buy) | 204,379 | 5.48 | 1.12M | 0 | — | ↗ |
| 2021-10-28 | Feder Julie B | Officer | — | D | Stock Option (Right to Buy) | 18,248 | 3.15 | 57.5K | 0 | — | ↗ |
| 2021-10-28 | De Rosch Mark | Officer | A-Award | A | Common Stock | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2004-02-29 | MEEHAN NEAL F | Officer | — | D | Common Stock | 0 | 0.00 | — | 93,750 | — | ↗ |
| 2003-09-25 | MEEHAN NEAL F | Officer | A-Award | A | Common Stock | 3,500,000 | 0.07 | 241.5K | 3,500,000 | — | ↗ |
| 2003-08-20 | MEEHAN NEAL F | Officer | A-Award | A | Common Stock | 3,000,000 | 0.08 | 240.0K | 3,000,000 | — | ↗ |
| 2003-08-20 | HARRINGTON JAMES S | Director | — | D | Aura Systems, Inc, Shares Common Stock | 0 | 0.00 | — | 1,500,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
64.20M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Elisabet de los Pinos, Ph.D. President, Chief Executive Officer and Director | 431.8K | 70.5K | 1.04M | 5.10M | 157.5K | 16.8K | 6.82M | 90.07% | ↗ |
| 2 | 2021 | Cadmus C. Rich, M.D. Chief Medical Officer and Head of Research & Development | 392.8K | — | 367.5K | 1.47M | 154.0K | 17.4K | 2.40M | 76.48% | ↗ |
| 3 | 2021 | Julie B. Feder Chief Financial Officer | 360.4K | — | 367.5K | 1.47M | 145.0K | — | 2.34M | 78.40% | ↗ |
| 4 | 2020 | Elisabet de los Pinos, Ph.D. President, Chief Executive Officer and Director | 394.9K | 148.9K | — | 534.0K | — | 17.1K | 1.09M | 48.77% | ↗ |
| 5 | 2020 | Cadmus C. Rich, M.D. Chief Medical Officer and Head of Research & Development | 377.3K | 124.5K | — | 113.5K | — | 17.1K | 632.4K | 17.95% | ↗ |
| 6 | 2020 | Julie B. Feder Chief Financial Officer | 343.2K | 113.2K | — | 95.9K | — | — | 552.3K | 17.36% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Elisabet de los Pinos | Founder, Chief Executive Officer, President & Director | 950.5K | — |
| Jill Hopkins | Chief Medical Officer & President of Research and Development | 792.8K | — |
| Conor Kilroy | Chief Legal Officer & Secretary | 611.2K | male |
| Anthony S. Gibney | Chief Financial & Business Officer | 604.1K | male |
| Natalie C. Holles | President, CEO & Director | — | female |
| Patrick Nealon | Senior Vice President of Clinical Development Operations | — | male |
| Amy Elazzouzi | Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer | — | female |
| Sabine Brookman-May | Senior Vice President & Therapeutic Area Head of Urologic Oncology | — | — |
| Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology | — | — |
| Joe McQuaid | VP & Therapeutic Area Head of Urologic Oncology | — | male |
| Mark Plavsic | Chief Technology Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AURA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
